A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma

Overview

A non-profit study designed with the aim of analysing the phenotype and molecular characteristics (central review) and evaluating prospectively the role of PET-scans in the management of primary mediastinal lymphoma treated with conventional approaches.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: May 2011

Clinical Trial Outcome Measures

Primary Measures

  • response rate on PET scanning following initial chemo-immunotherapy

Participating in This Clinical Trial

Inclusion Criteria

  • Primary mediastinal diffuse large B-cell lymphoma, CD20 positive. Patients must have histological confirmation of the diagnosis, and in addition have a dominant mass within the anterior mediastinum. – No prior treatment of lymphoma. Patients may have received corticosteroids for up to 1 week for the relief of local compressive symptoms. – Any stage of disease. – Age at least 18 years. – Fit to receive chemotherapy with curative intent. – Able and willing to give informed consent, and to undergo staging including PET scanning – Willingness to comply with an appropriate contraceptive method in women of childbearing potential or men. Exclusion Criteria:

  • Evidence of clinically significant cardiac disease, as defined by history of symptomatic ventricular arrhythmias, congestive heart failure or myocardial infarction within 12 months before study entry. Cardiac compromise due to local extension of lymphoma will not be an exclusion criterion in the absence of other cardiac disease. – Impairment of bone marrow function (WBC <3.0×109/L, ANC <1.5×109/L, PLT <100×109/L), unless due to involvement by lymphoma. – Major impairment of renal function (serum creatinine >2x upper normal) or liver function (ASAT/ALAT >2,5 upper normal, total bilirubin >2,5x upper normal), unless due to lymphoma involvement. – Known HIV infection. Patients will not be tested routinely. – Pregnant or lactating women. – Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • International Extranodal Lymphoma Study Group (IELSG)
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.